Myriad Genetics Inc. has made headlines with the announcement of the departure of Brian Donnelly, its former Chief Commercial Officer. This change, effective September 21, 2026, comes as the company seeks to navigate its strategic direction amidst a competitive landscape in the diagnostics industry.
Myriad Genetics, based in Salt Lake City, Utah, operates within the In Vitro & In Vivo Diagnostic Substances sector, as classified under the Standard Industrial Classification (SIC) code 2835. The company is listed on the Nasdaq under the ticker MYGN. Recently, it has been active in filing various reports, including a recent 8-K on October 9, 2026.
According to the filing, Myriad Genetics entered into a Separation Agreement and Release of Claims with Donnelly. The agreement stipulates that he will receive a severance payment of $1,322,294, contingent upon his compliance with certain restrictive covenants. This includes non-solicitation and non-disparagement clauses, which are standard in such agreements. The agreement becomes effective on October 14, 2026, unless Donnelly revokes it before that date.
In addition to the severance payment, Donnelly's outstanding equity awards will be accelerated, allowing for earlier vesting. This includes time-based equity awards that were set to vest within two years following his separation date. Performance-based awards will remain outstanding and could vest if the relevant conditions are met within the same timeframe.
This departure and the accompanying severance package may impact various stakeholders, including employees, investors, and competitors in the diagnostics industry. Myriad Genetics is known for its innovative approaches to genetic testing and diagnostics, making leadership changes particularly significant in this rapidly evolving market.
As for what comes next, the filing does not specify any immediate subsequent actions beyond the effective date of the separation agreement. However, industry observers will likely be watching closely for any further developments regarding the company's strategic direction and leadership structure.